Iricryn (Bimatoprost)

Bimatoprost binds to prostaglandin F‑type (FP) receptors in the ciliary body, activating a cascade that remodels extracellular matrix proteins. This remodeling increases the uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure. The effect is sustained with once‑daily dosing and does not significantly alter aqueous humor production.

The dosing regimen for Iricryn is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing are individualized based on the patient’s intra‑ocular pressure response and tolerability. Patients should follow the prescriber’s instructions precisely.

Safety data for bimatoprost in pregnancy and lactation are limited. The drug is classified as contraindicated or to be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Iricryn, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iricryn (bimatoprost) belongs to the prostaglandin analog class, which generally provides greater intra‑ocular pressure reduction than beta‑blockers or carbonic anhydrase inhibitors. Compared with other prostaglandin analogs such as latanoprost, bimatoprost may have a slightly higher efficacy but a similar safety profile, with the added possibility of more pronounced eyelash growth.

Iricryn should be stored at room temperature, preferably below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light, and avoid exposure to moisture. Do not freeze the solution. If the product has been opened for longer than the period indicated on the label, discard it and obtain a new supply.

Iricryn is applied as an ocular solution. The patient should wash their hands, tilt the head back, and gently pull down the lower eyelid to create a pocket. One drop is placed into the conjunctival sac of the affected eye(s) without touching the tip of the bottle to the eye or lashes. The eye should be closed gently for a minute to aid absorption.

Although uncommon, serious adverse events can occur. These include severe eye inflammation (uveitis), paradoxical increase in intra‑ocular pressure, and corneal edema or ulceration, which may threaten vision. If any of these symptoms develop—such as worsening pain, redness, vision loss, or swelling—treatment should be stopped immediately and urgent ophthalmologic evaluation sought.

Iricryn is contraindicated in patients with known hypersensitivity to bimatoprost or any component of the formulation. It should also be avoided in individuals with active ocular infections, recent ocular surgery, or uncontrolled ocular inflammation. Caution is advised for patients using contact lenses, as the medication may cause lens discoloration. The prescriber must assess each patient’s medical history before initiating therapy.